An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Tipelukast (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors MediciNova
- 29 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 29 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 28 Jan 2018 According to a MediciNova media release, interim results from this trial has been accepted for poster presentation at the International Liver Congress 2018, the 53rd annual meeting of the European Association for the Study of the Liver (EASL).